Potential drug treats fatty liver disease in animal models, brings hope for first human treatment

A potential drug successfully treats the severe form of nonalcoholic fatty liver disease in non-human primates — bringing scientists one step closer to the first human treatment for the condition that is rapidly increasing around the world, a study suggests. Nonalcoholic steatohepatitis (NASH) causes scarring and inflammation in the liver and is estimated to affect up to 6.5% of the global population.

Alternate-day fasting a good option for patients with fatty liver disease

Nutrition researchers studied 80 people with nonalcoholic fatty liver disease and found that those who followed an alternate-day fasting diet and exercised were able to improve their health. In Cell Metabolism, the researchers report that over a period of three months people in the intervention saw increased insulin sensitivity and decreased liver fat, weight and ALT, or alanine transaminase enzymes, which are markers for liver disease.

August Issue of Issue of The American Journal of Gastroenterology Includes Diet-Associated NAFLD Risk and Increased Risk of Mortality from COVID-19 Among PPI Users

The August issue of The American Journal of Gastroenterology includes clinical discussions of diet-associated NAFLD risk and increased risk of mortality from COVID-19 among PPI users. In addition, this issue features clinical research and reviews on IBS, gender barriers for CRC screening, hepatitis C, eosinophilic esophagitis, and more.

January Issue of The American Journal of Gastroenterology Includes New Clinical Guideline on Irritable Bowel Syndrome

The January issue of The American Journal of Gastroenterology is now available and features new clinical research across a wide range of GI and hepatology topics, including NAFLD, colorectal cancer screening, GERD, post-COVID-19-associated functional GI disorder surges, celiac disease, and more.

Cirrhosis in North American Women on the Rise, Trend Especially Worrisome in Young Women

Data from a new study presented this week at The Liver Meeting Digital Experience® – held by the American Association for the Study of Liver Diseases – found that the burden of cirrhosis in women in North America has increased substantially in recent years, a worrying trend driven by a rise in alcohol-related liver disease (ALD) and nonalcoholic fatty liver disease (NAFLD). Projections suggest that both ALD and NAFLD rates will result in even higher cirrhosis incidence by 2040, with the most worrisome upward trends seen in young women with ALD and post-menopausal women with NAFLD.

Researchers Identify Potential Early Biomarker to Track Development of Dangerous Non-alcoholic Fatty Liver Disease

Fatty liver disease not associated with alcohol consumption, which is called Nonalcoholic Fatty Liver Disease or NAFLD, affects more than one billion people worldwide. Even in children the numbers are overwhelming, with up to 80 percent of pediatric patients who are considered obese affected worldwide. People with NAFLD can progress to a severe form known as nonalcoholic steatohepatitis (NASH), which puts patients at higher risk for cirrhosis or liver cancer.